Next Article in Journal
Regenerative Potential of the Product “CardioCell” Derived from the Wharton’s Jelly Mesenchymal Stem Cells for Treating Hindlimb Ischemia
Next Article in Special Issue
More Than an Adipokine: The Complex Roles of Chemerin Signaling in Cancer
Previous Article in Journal
PTEN, A Target of Microrna-374b, Contributes to the Radiosensitivity of Canine Oral Melanoma Cells
Previous Article in Special Issue
Involvement of Novel Adipokines, Chemerin, Visfatin, Resistin and Apelin in Reproductive Functions in Normal and Pathological Conditions in Humans and Animal Models
Article

Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis

1
Rheumatology Unit, Carmel Medical Center, Haifa 3436212, Israel
2
The Immunotherapy Laboratory, Carmel Medical Center, Haifa 3436212, Israel
3
The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 3109601, Israel
4
Rheumatology Unit, Bnai Zion Medical Center, Haifa, 3339419, Israel
5
Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa 3436212, Israel
*
Author to whom correspondence should be addressed.
These authors contributed equally to the manuscript.
Int. J. Mol. Sci. 2019, 20(18), 4633; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms20184633
Received: 17 August 2019 / Revised: 14 September 2019 / Accepted: 16 September 2019 / Published: 18 September 2019
(This article belongs to the Special Issue Adipokines 2.0)
Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease. Dyslipidemia is a known adverse effect of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody used in RA treatment. We aimed to assess the effect of TCZ on lipid profile and adipokine levels in RA patients. Height, weight, disease activity scores, lipid profile and atherogenic indices (AI), leptin, adiponectin, resistin, interleukin-6, and high-sensitivity C-reactive protein (CRP) were measured before and four months after initiation of TCZ in 40 RA patients and 40 healthy controls. Following TCZ treatment, total cholesterol, high density lipoprotein (HDL), and triglycerides were significantly elevated, but no significant changes in weight, body mass index (BMI), low density lipoprotein (LDL), and AI were observed. Compared with controls, significantly higher adiponectin levels were measured in the RA group at baseline. Following TCZ treatment, resistin levels and the leptin-to-adiponectin ratio increased, adiponectin levels decreased, and leptin levels remained unchanged. No correlation was found between the change in adipokine serum levels and changes in the disease activity indices, nor the lipid profile. In conclusion, the changes observed suggest a protective role for TCZ on the metabolic and cardiovascular burden associated with RA, but does not provide a mechanistic explanation for this phenomenon. View Full-Text
Keywords: rheumatoid arthritis; tocilizumab; lipids; adipokines; adiponectin; resistin; leptin rheumatoid arthritis; tocilizumab; lipids; adipokines; adiponectin; resistin; leptin
MDPI and ACS Style

Hoffman, E.; Rahat, M.A.; Feld, J.; Elias, M.; Rosner, I.; Kaly, L.; Lavie, I.; Gazitt, T.; Zisman, D. Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis. Int. J. Mol. Sci. 2019, 20, 4633. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms20184633

AMA Style

Hoffman E, Rahat MA, Feld J, Elias M, Rosner I, Kaly L, Lavie I, Gazitt T, Zisman D. Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis. International Journal of Molecular Sciences. 2019; 20(18):4633. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms20184633

Chicago/Turabian Style

Hoffman, Elinoar, Michal A. Rahat, Joy Feld, Muna Elias, Itzhak Rosner, Lisa Kaly, Idit Lavie, Tal Gazitt, and Devy Zisman. 2019. "Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis" International Journal of Molecular Sciences 20, no. 18: 4633. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms20184633

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop